Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > NEWS
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(58)
•••
Comment by whisky11on Apr 05, 2021 9:20pm
189 Views
Post# 32939493

RE:NEWS

RE:NEWS
mavericks2020 wrote:

 

Kalytera, Salzman licence agreement amended

 

2021-04-05 20:26 ET - Property Agreement

 

The TSX Venture Exchange has accepted for filing an amendment of licence agreement dated Feb. 17, 2021, between Salzman Group Inc., a Delaware corporation, Salzman Group Ltd., an Israeli corporation, and Salzman Group Pty. Ltd., an Australian corporation (collectively the Salzman Group), and Kalytera Therapeutics Inc., whereby the company may acquire a licence to develop and commercialize R-107 with a licensc fee of $1.2-million (U.S.) and the issuance of 130 million common shares of the company to the Salzman Group. Further considerations include a success fee of $2-million (U.S.) based on certain milestone and additional milestone payments in stages in the cash amount of $4.25-million (U.S.).

© 2021 Canjex Publishing Ltd. All rights reserved.


whisky11:. Something big happening!!!

If you describe someone or something as the real McCoy, you meanthat they really are what they claim to be and are not an imitation.
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities